PT  - JOURNAL ARTICLE
AU  - LeAnne Hutson
AU  - Joy Obuekwe
TI  - Acute Myeloid Leukemia – Down Syndrome: A Case Study from a Children’s Hospital
AID  - 10.29074/ascls.2020002840
DP  - 2020 Aug 01
TA  - American Society for Clinical Laboratory Science
4099  - http://hwmaint.clsjournal.ascls.org/content/early/2023/04/10/ascls.2020002840.short
4100  - http://hwmaint.clsjournal.ascls.org/content/early/2023/04/10/ascls.2020002840.full
AB  - Congenital conditions like Down syndrome have been associated with increased risk for clonal disorders that affect megakaryocytic lineage. The World Health Organization has classified acute myeloid leukemia – Down syndrome (ML-DS) as a specific subtype of acute myeloid leukemia. Studies have shown that children with ML-DS have a better prognosis than children without Down syndrome with a long-term survival rate of 74%–91%. One possible explanation for this differentiation is that the megakaryoblast cells in ML-DS have increased sensitivity to cytotoxic drugs like cytarabine-based therapy. This has been attributed to the GATA1-mutant isoform decreased expression of cytidine deaminase and the overexpression of the cystathionine-β–synthase, a chromosome 21–localized gene present in ML-DS megakaryoblast cells. This case study followed the course of diagnosis and treatment of a 17-month-old patient with ML-DS. GATA1 mutation was confirmed in this case, and flow cytometry identified a megakaryoblast population expressing cluster differentiation markers of CD13, CD33, CD34, CD7, CD36, CD41, CD61, CD71, and CD117 in approximately 43.5% of the sample. As a result of the flow cytometry, physicians confirmed ML-DS as the diagnosis. The patient received 2 rounds of a chemotherapy treatment that included a combination chemotherapy regime with intrathecal chemotherapy to prevent relapse. Within 1 month of treatment, the patient was in remission and has remained with negative minimal residual disease to date.